CAR T Cell therapy market is expected to grow with a CAGR of over 46 percent in the forecast period. Year 2017 has created new milestone for the oncology patients as FDA approved the first two CD19-targeted (Chimeric Antigen Receptor) CAR T cell therapies developed by Novartis and Gilead Sciences/Kite Pharma in the United States. These two approvals will certainly help to boost the global CAR T cell therapy market as more players are looking this big opportunities to enter the market place. At present over 200 CAR T clinical trials are running or completed across various parts of the world.

Rising number of adults and children developing cancer, increasing government initiatives for promoting research for cell therapy in cancer and rising number of clinical trials globally are some of the key drivers for the global CAR T Cell therapy market; however high cost of CAR T cell therapy treatment and regulatory challenges are key inhibitors for this market.

Renub Research latest study report “CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others) Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33,HER1, HER2, MESO, EGFRvII) Companies (Novartis,Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad)” provides a detailed and comprehensive insight of the global CAR T cell therapy market.

This report studies the Global CAR T cell therapy market from 2 key view points by CAR T cell therapy market and CAR T cell therapy studies. Market segments are further studied by geographical regions and targeted antigens whereas CAR T cell therapy studies by targeted antigens globally and China specific. The report provides a complete analysis of the key Growth Drivers and Challenges, SWOT analysis, market, and their projections for the upcoming years (2028).


The report has been analyzed from 9 major viewpoints

1. Targeted Antigen - Global CAR T Cell Therapy Market
2. Regional CAR T Cell Therapy Market
3. Global – CAR T Cell Therapy Clinical Trials/Study
4. China CAR T Cells Clinical Trials Details
5. CAR T Cell Therapy SWOT Analysis
6. The Regulation in CAR T Cell Therapy
7. Global - IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market
8. Growth Drivers and Challenges
9. Key CAR T companies Initiatives and Financial Insight


Targeted Antigens - Global CAR T Cell Therapy Market & Forecast

  • CD19
  • CD20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER2
  • MESO
  • EGFRvII
  • Others




Regional CAR-T Cell Therapy Market & Forecast

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa




Global – CAR T Cell Therapy Clinical Trials/Study

  • CD19
  • CD20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • HER2
  • MESO
  • EGFRvII




China CAR T Cells Clinical Trials Details

  • By Cities CAR T Cells Clinical Trials
  • CD19 Directed CAR T Cells Clinical Trials
  • Non-CD19 Directed CAR T Cells Clinical Trials
  • Solid Tumors CAR T Cells Clinical Trials




The Regulation in CAR T Cell Therapy

  • United States
  • European Union
  • China




IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market

  • Venture Capital Investment
  • Initial Public Offerings
  • Strategic Partnerships/Deals
  • Key CAR T Technology Deals




Key Companies covered in this report are

  • Novartis
  • Gilead Sciences (Kite Pharma)
  • Celgene Corporation (Juno Therapeutics)
  • Celyad